Of major importance are two recent studies that demonstrate/confirm CDK12 is a tumor suppressor for ovarian and prostate cancers and go on to show that bi-allelic loss of CDK12 in ovarian or prostate tumor cells leads to large numbers of tandem duplications spread throughout the genome [27,28]. Here, CDK12 is linked to neoplasm.